In Vitro Diagnostic Contract Manufacturing Buyer Guide

19Oct 2026

IVD Manufacturing IVDCDMO Team Comments: 0

Regulatory status checked on 30 September 2026

In vitro diagnostic contract manufacturing allows a diagnostics company to outsource the production of reagents, test kits, cartridges or instruments to a specialist manufacturer. It can reduce the need to build a factory and provide access to established production capabilities. Its value depends on whether the partner can repeatedly deliver products that meet the approved specifications, with the records needed to support release and regulatory oversight.

For buyers, the decisive questions concern batch consistency, technical transfer, access to data and continuity of supply. A competitive quotation is useful only when those questions have credible answers.

This guide explains how to assess an IVD contract manufacturer, structure a transfer project and compare commercial proposals. It focuses on commercially supplied diagnostic products, with particular attention to the United States and European Union.

What In Vitro Diagnostic Contract Manufacturing Includes

The scope can range from a single operation, such as reagent filling, to complete kit production and distribution. Typical services include raw material qualification, formulation, coating or conjugation, drying, assembly, packaging, quality control and batch documentation. Instrument projects may also involve electronics, firmware configuration, calibration and servicing.

Three commercial terms deserve careful interpretation:

Contract manufacturing generally means production against an agreed design and specifications, although the manufacturer may also provide process engineering.
Contract development and manufacturing, or CDMO, adds defined development work, such as assay optimization, formulation development or design for manufacture.
OEM and private label supply may involve an existing platform or product sold under another commercial identity. The agreement must establish the regulatory manufacturer, permitted claims and access to supporting documentation.

These labels do not determine regulatory responsibility. In the EU, the manufacturer can be the company that has a device designed or manufactured by another organization and markets it under its name or trademark. Identify the legal manufacturer before agreeing on labeling and market access. FAMHP

When Outsourcing Makes Commercial Sense

Outsourcing is attractive when the required manufacturing capability is expensive, specialized or needed sooner than an internal facility could be established. A company with strong assay development expertise may need external capabilities in automated strip production, lyophilization or precision cartridge assembly.

It can also support an established business that needs additional capacity or a second production location. In either case, compare the full alternatives: internal staffing and equipment, supplier qualification, transfer costs, ongoing oversight and the cost of maintaining an exit option.

Keeping production internally may be preferable when manufacturing knowledge is the core intellectual property, the process is still changing frequently, or a qualified external supplier cannot provide the necessary access and control. A hybrid arrangement is also possible. Critical biological materials can remain under the product owner’s control while filling, assembly or packaging is outsourced.

The choice should follow the product’s technical and commercial requirements. Geography and headline labor cost are incomplete selection criteria.

Regulatory Requirements That Matter in 2026

United States FDA QMSR Is Already in Effect

The FDA’s Quality Management System Regulation, or QMSR, became effective on 2 February 2026. It incorporates ISO 13485:2016 by reference into 21 CFR Part 820, with additional FDA requirements. Applicable finished device manufacturers must work under the current framework, subject to relevant exemptions. FDA

An ISO 13485 certificate does not exempt a manufacturer from FDA inspection. The FDA also states that management review records, quality audits and supplier audit reports are available for inspection under QMSR. Buyers should assess the evidence behind a supplier’s quality system, including how deficiencies are investigated and resolved. FDA

Separately, FDA establishment registration and device listing do not establish approval, clearance or authorization. Determine the product’s applicable market pathway and verify any claimed authorization against the actual device, intended use and responsible company. FDA

European Union IVDR Transition Dates Require Eligibility Checks

Regulation (EU) 2024/1860 extended transition periods for qualifying legacy IVDs. The principal end dates are:

Qualifying legacy device category	Transition end date
Devices covered by qualifying IVDD certificates and qualifying Class D devices	31 December 2027
Qualifying Class C devices previously self-declared under the IVDD	31 December 2028
Qualifying Class B and Class A sterile devices previously self-declared under the IVDD	31 December 2029

Eligibility requires continued IVDD compliance, no significant design or intended purpose changes, no unacceptable risk, an IVDR quality system established by 26 May 2025, and timely notified body applications and agreements. hpra.ie

For the relevant legacy Class C devices, applications were due by 26 May 2026 and written agreements by 26 September 2026. Both deadlines have passed. Verify compliance before relying on the 2028 end date. Newly introduced IVDs do not automatically qualify for these legacy provisions. hpra.ie

Manufacturing Validation and Diagnostic Performance Are Separate

Process validation demonstrates that a manufacturing process consistently produces outputs meeting its specifications. It cannot, by itself, establish the diagnostic performance of the product.

Under the IVDR framework, performance evaluation addresses scientific validity, analytical performance and, where applicable, clinical performance. These establish the relationship between the analyte and the clinical condition, the device’s ability to detect or measure it, and the relevance of the results in the intended clinical context. health.ec.europa.eu

A transfer project needs both manufacturing evidence and a justified assessment of whether existing product performance evidence remains applicable after the transfer.

How to Transfer an IVD Assay Into Commercial Production

Define the Product and Acceptance Criteria

Start with the intended use, specimen types, intended users, instrument compatibility, storage conditions and proposed claims. Then establish measurable product specifications and the methods used to assess them.

For a qualitative assay, pay particular attention to performance around the decision threshold. For a quantitative assay, relevant criteria may include precision, bias, measuring interval and calibration behavior. The exact requirements depend on the product and its regulatory pathway.

Agree on acceptance criteria before producing transfer batches. Otherwise, a passing result may mean different things to the product owner and the factory.

Transfer Manufacturing Knowledge and Controlled Documents

A usable transfer package normally contains the bill of materials, approved supplier details, material specifications, formulation instructions, process parameters, drawings, test methods, packaging specifications and controlled labeling.

Include the details that explain how the assay behaves during production. Mixing sequence, hold time, drying conditions and reagent handling can matter even when the final formulation is unchanged. Instructions should allow trained production staff to reproduce the process without relying on an individual developer’s memory.

Agree on which documents the customer receives, which remain supplier confidential and how regulators can access necessary information. A project can produce acceptable samples yet leave the customer unable to support a submission or transfer production elsewhere.

Establish Comparability and Validate Relevant Processes

Use engineering batches to identify differences between the original process and the receiving site. Assess changes in equipment, materials, operators and environmental conditions against product risk and performance.

Where process outputs cannot be fully verified through subsequent inspection or testing, validation is necessary under the applicable quality requirements. A common structure uses installation qualification, operational qualification and performance qualification to address equipment installation, operating limits and routine production performance. GHTF guidance provides a practical explanation of this approach. Process Validation Guidance -January 2004

The protocol should justify the number of runs, lots and samples, the conditions challenged and the acceptance criteria. A fixed batch count alone does not establish that a process is adequately validated.

If critical materials or manufacturing conditions change, determine whether additional analytical, stability or clinical evidence is needed. This assessment should precede commercial release.

Confirm Stability and Shipping Conditions

Shelf life affects ordering, working capital and the viability of distribution. Separate unopened shelf life from stability after opening, after reconstitution and during use, where relevant.

WHO’s guidance for IVD prequalification normally bases shelf-life claims on real-time experimental results. Accelerated studies have a supporting role, with defined circumstances in which they may be considered while real-time data are generated. The guidance also addresses transport stress. It is a useful technical reference; its prequalification requirements should not be presented as universal rules for every market. extranet.who.int

For procurement, ask for the evidence supporting the actual proposed packaging and shipping route. Specify the minimum remaining shelf life at delivery and an agreed method for assessing temperature excursions.

Agree on Release and Ongoing Monitoring

Define who performs manufacturing release, who reviews the records and who authorizes commercial distribution. Specify the release package, including applicable test results, deviation assessments and material traceability.

After launch, review trends in yield, invalid results, complaints, deviations and relevant assay measurements. A gradual movement toward a specification limit can warrant investigation before a batch fails. Establish escalation rules and responsibilities for corrective action.

Match the Manufacturer to the Diagnostic Technology

Experience with one IVD format does not establish competence in another. Use the following as a starting point for technical assessment, then adapt it to the assay.

Product format	Production capability to assess	Evidence to request
Lateral flow tests	Reagent dispensing, membrane handling, drying, cutting and pouch sealing	Lot comparison data, results near the cutoff, and packaging and moisture controls
Molecular diagnostic reagents	Contamination prevention, enzyme handling, dispensing and drying where applicable	Contamination investigations, relevant analytical performance data and stability results
Immunoassay reagent kits	Biological material consistency, coating or conjugation, calibration and filling	Raw material acceptance criteria, calibration traceability and lot comparison results
Diagnostic cartridges	Precision molding, fluid handling, reagent integration and sealing	Assembly validation, leak or functional testing and assay performance after assembly

For instrument-based assays, define the reader, firmware, calibration and consumables as a system. A reagent that performs well on one configuration may require additional assessment on another.

Ask whether the quoted capacity applies to the proposed product and its quality control requirements. Filling throughput alone does not describe the capacity to release finished kits.

Assess Batch Consistency With Meaningful Evidence

An audit should connect procedures to actual records. Request examples from a comparable product or process, with confidential details removed where necessary.

Review a batch record alongside its raw material results, in-process measurements, final tests and deviations. This shows whether the supplier can reconstruct what happened and explain why the batch was released.

For biological raw materials, determine how replacement lots are qualified. A supplier’s certificate of analysis may cover identity and purity while leaving important assay behavior untested. Consider product-specific incoming tests for critical antibodies, antigens, enzymes or membranes.

Release panels also deserve scrutiny. Strong positives and clear negatives may provide limited information about a qualitative assay drifting near its cutoff. Quantitative assays need controls that challenge relevant parts of the measuring interval. The panel, sample matrix and acceptance limits should be justified for the assay.

Discuss actual failure handling. Ask how the team distinguishes equipment problems, material variation and analytical test issues, and how it prevents an unresolved failure from being concealed through repeated testing.

How Much In Vitro Diagnostic Contract Manufacturing Costs

A useful budget separates one-time project costs from recurring supply costs. One-time costs may include development, transfer, tooling, equipment changes, method validation, process validation, stability studies and regulatory documentation. Recurring costs can include materials, conversion, quality control, packaging, storage and freight.

Request an itemized quotation with explicit assumptions about volume, yield, batch size, testing and responsibility for rejected product. Ask what happens commercially if those assumptions prove incorrect.

Compare Cost per Accepted Released Unit

The basis of the price matters. Consider this illustrative calculation, which is not an industry price benchmark:

Supplier A charges $1.00 per unit entering production. At 90% released yield, that cost is approximately $1.11 per accepted unit.
Supplier B charges $1.05 on the same basis. At 98% released yield, the corresponding cost is approximately $1.07 per accepted unit.

Supplier B has the lower cost on this limited comparison despite its higher starting price. The example excludes transfer costs, freight and other charges. If a quotation already prices delivered, accepted units and includes scrap, do not adjust it for yield again.

Also examine minimum order quantities. MOQ can mean a production batch, an order, a packaging run or a material purchasing commitment. Those obligations create different inventory risks. For products with limited shelf life, confirm that the order quantity can realistically be sold or used before expiry.

Establish a Quality Agreement and an Exit Plan

The commercial contract addresses price, payment and liability. A quality agreement should allocate the operational responsibilities that protect the product and its supporting evidence.

Cover, at minimum:

Approval of specifications and manufacturing instructions, with defined responsibilities for batch release.
Control of critical suppliers, subcontractors and changes to materials, methods, equipment or production location.
Notification and investigation of deviations, failed results, complaints and regulatory inspection findings.
Access to records, raw data and retained samples, with appropriate retention arrangements.
Audit rights and cooperation with regulators and conformity assessment bodies.
Responsibilities for field actions, product recalls and supply interruption.

Change control requires particular care. Define which changes need prior approval, how their effect on performance and regulatory status is assessed, and who pays for supporting work. Supplier notification should arrive early enough for the customer to make a decision.

Intellectual property provisions should distinguish pre-existing supplier technology from project-specific results. Specify ownership or use rights for formulations, test methods, tooling, software and generated data. Paying for development does not automatically settle those rights.

Finally, define an executable exit process. Agree on access to customer-owned tooling, transfer assistance, usable document formats and permitted use of necessary know-how. A second factory can only become a practical alternative if the information and rights required for transfer are available.

Build the Timeline Around the Actual Dependencies

Separate the schedule for engineering samples, qualified production batches, supporting studies, regulatory milestones and routine commercial supply. Each has different prerequisites.

Long lead materials, tooling, reference materials and access to suitable specimens can delay a project before factory capacity becomes relevant. Stability studies and regulatory assessment may continue after manufacturing work is complete.

Ask the supplier to identify the critical path and the evidence required at each milestone. Include decision points for design changes and failed studies. A credible schedule explains its assumptions and the consequences when they change.

What to Include in an IVD Manufacturing RFQ

Give shortlisted suppliers the same project brief so their proposals can be compared. Include:

The analyte, intended use, specimen types, users and target markets.
The assay format, instrument configuration and current development stage.
Available performance evidence and the manufacturing information ready for transfer.
Required production operations and the work retained by the customer.
Expected annual demand, launch quantity and batch size assumptions.
Product specifications, packaging, storage and minimum remaining shelf life at delivery.
Requested documentation, regulatory support and allocation of release responsibilities.
Milestones, intellectual property requirements and expectations for future transfer.

Request exclusions as well as deliverables. A proposal that leaves out reference materials, failed-batch investigations or ongoing stability work can appear inexpensive while creating later costs.

Frequently Asked Questions

What Is the Difference Between an IVD Contract Manufacturer and an IVD CDMO

An IVD contract manufacturer primarily performs agreed production activities. An IVD CDMO also undertakes defined development work. The practical difference lies in the statement of work, acceptance criteria and ownership of the results.

Does ISO 13485 Certification Establish Market Authorization

No. Certification concerns a quality management system within its stated scope. It does not establish authorization for a particular diagnostic product or replace the applicable regulatory assessment. FDA registration and listing are also distinct from approval, clearance and authorization. Requirements for regulatory purposes

Can an Existing IVD Product Be Supplied Under a New Brand

Potentially, but the arrangement needs a product-specific regulatory assessment. Establish the legal manufacturer, labeling responsibilities, permitted claims and access to technical documentation before agreeing to a private label launch.

Can Commercial Production Start Before All Stability Studies Finish

Manufacturing, release and lawful distribution are separate decisions. The proposed shelf-life claim needs adequate supporting evidence under the applicable pathway. Any use of accelerated data or an initial shorter shelf life must be justified; the production schedule should not determine the claim. extranet.who.int

Can a Manufacturing Transfer Change Diagnostic Performance

Yes. Changes in critical materials, equipment or processing conditions can affect assay behavior. Assess those changes through a risk-based comparability plan and determine what additional evidence is needed before release.

Choosing an IVD Manufacturing Partner

Successful in vitro diagnostic contract manufacturing depends on a partner’s ability to reproduce the product, explain its production history and maintain control as materials, demand and processes change.

Before committing to commercial supply, establish four deliverables: agreed product specifications, a justified transfer and validation plan, a clear quality agreement and a quotation based on defined release requirements. These give the buyer a practical basis for evaluating cost, performance and accountability throughout the relationship.

Author Profile

IVDCDMO Team: Written by the IVDCDMO technical and regulatory team, with expertise in diagnostic assay development, GMP manufacturing, ISO 13485 systems, and global IVD commercialization for biotech innovators worldwide.